ALDH2 and cardiomyopathy: Administration of Alda-1/chaetocin, aimed at enhancing ALDH2 activity, exhibited therapeutic potential by mitigating the impact of palmitic acid on autophagy and contractile function, suggesting a broader role for ALDH2 in obesity-related cardiomyopathy [31].